Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
March 4, 2024 updated by: Laurenti Patrizia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cost-consequence Analysis of Influenza Vaccination Among the Staff of a Large Teaching Hospital in Rome, Italy: A Pilot Study
Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity.
Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low.
The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
5483
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rome, Italy, 00168
- Fondazione Policlinico Universitario "A.Gemelli" IRCCS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The study population is represented by all employed healthcare workers of the FPG amounting to approximately 5000 (data provided by the Human Resources Department of the Hospital in December 2017).
The case group consists of all healthcare workers vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital, filed on special registers.
The control group consists of healthcare workers who were not vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital.
Description
Inclusion Criteria:
• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS
Exclusion Criteria:
• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Vaccinated subjects
Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration
|
Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
|
|
Unvaccinated subjects
Healthcare workers that did not received flu vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness of the quadrivalent vaccine
Time Frame: 33 weeks
|
Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome
|
33 weeks
|
|
Economic impact of the quadrivalent vaccine
Time Frame: 33 weeks
|
Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital.
|
33 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Expected economic savings for each one percentage point increase in vaccination coverage
Time Frame: 33 weeks
|
Expected economic savings for each one percentage point increase in coverage on the health personnel of the teaching hospital
|
33 weeks
|
|
Non-economic incentives for healthcare personnel who decide to vaccinate
Time Frame: 33 weeks
|
Non-economic incentives for healthcare personnel who decide to vaccinate, in view of the financial savings for the company, linked to increased vaccination coverage
|
33 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2017
Primary Completion (Actual)
April 29, 2018
Study Completion (Actual)
November 14, 2019
Study Registration Dates
First Submitted
March 11, 2023
First Submitted That Met QC Criteria
March 4, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 4, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.